Experimental drug COH29 targets tumor growth enzyme in advanced cancers

NCT ID NCT02112565

Ongoing Disease control Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This early-phase trial tests an experimental drug called COH29 in people with advanced solid tumors that have stopped responding to standard treatments or have no standard therapy available. COH29 works by blocking an enzyme that cancer cells need to grow and multiply. The main goals are to find the safest dose and understand the drug's side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: COH29 (a drug that blocks an enzyme tumors need to grow)
What this could lead to: If safe and effective, COH29 could offer a new treatment option for people with advanced solid tumors that have stopped responding to other therapies.
What could go wrong: This is a very early, small Phase 1 trial focused on safety and dosing, not on proving the drug works. Many experimental cancer drugs fail in early testing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC

Contacts and locations

Show contact details

Locations

City of Hope Medical Center

Duarte, California, 91010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.